Critical Therapeutics Announces Changes to Board of Directors.Former Bristol-Myers Squibb Bristol-Myers Squibb (NYSE: BMY), colloquially referred to as BMS, is a pharmaceutical corporation, formed by a 1989 merger between pharmaceutical companies Bristol-Myers Company, founded in 1887 by William McLaren Bristol and John Ripley Myers in Clinton, NY (both were Executive Cory Zwerling Appointed as Director LEXINGTON, Mass. -- Critical Therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. , Inc. (Nasdaq: CRTX), a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases, today announced certain changes to the Company's board of directors. M. Cory Zwerling has been elected to the board of directors. Zwerling replaces H. Shaw Warren, M.D., a director since July 2000, who resigned from the board. Zwerling will serve for the remainder of Warren's term, which expires at the 2008 annual meeting of stockholders. Zwerling, 47, served in several positions of increasing responsibility with Bristol-Myers Squibb over the past 19 years, culminating in his appointment as president of Bristol-Myers Squibb Medical Imaging from 2002 to 2006. He holds a bachelor's degree in economics from Cornell University Cornell University, mainly at Ithaca, N.Y.; with land-grant, state, and private support; coeducational; chartered 1865, opened 1868. It was named for Ezra Cornell, who donated $500,000 and a tract of land. With the help of state senator Andrew D. and a master's degree master's degree n. An academic degree conferred by a college or university upon those who complete at least one year of prescribed study beyond the bachelor's degree. Noun 1. in applied economics and finance from M.I.T. Sloan School of Management. Zwerling will chair a Strategic Advisory Committee established by the board. "Cory's extensive background in global pharmaceutical sales and marketing will be an asset to the board, and we look forward to his contributions as we focus on the commercial opportunity for zileuton zileuton /zi·leu·ton/ (zi-loo´ton) an inhibitor of leukotriene formation, used as an antiasthmatic. Zileuton (Zyflo) CR," said Critical Therapeutics President Frank Thomas Frank Thomas may refer to:
Critical Therapeutics also announced that the board of directors has appointed Richard W. Dugan, a member of the board since April 2004, as lead independent director. Robert H. Zeiger stepped down as executive chairman of the Company, but will continue to serve as a director. About Critical Therapeutics Critical Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of products for respiratory, inflammatory and critical care diseases. The Company owns worldwide rights to the asthma drug ZYFLO([R]) (zileuton tablets), as well as other formulations of zileuton. ZYFLO is the only 5-lipoxygenase inhibitor inhibitor /in·hib·i·tor/ (in-hib´i-tor) 1. any substance that interferes with a chemical reaction, growth, or other biologic activity. 2. approved for marketing by the U.S. Food and Drug Administration. The Company's commercialization efforts for ZYFLO are carried out by its specialty sales force. Critical Therapeutics also is developing treatments directed toward the severe inflammatory response in acute diseases and conditions that lead to admission to the emergency room or intensive care unit, and acute exacerbations of other chronic diseases that frequently lead to hospitalization hospitalization /hos·pi·tal·iza·tion/ (hos?pi-t'l-i-za´shun) 1. the placing of a patient in a hospital for treatment. 2. the term of confinement in a hospital. . For more information, please visit www.crtx.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion